Search company, investor...

Anza Therapeutics

Stage

Unattributed VC | Alive

Total Raised

$18M

Last Raised

$18M | 15 yrs ago

About Anza Therapeutics

Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.

Headquarters Location

150 Allens Creek Road

Concord, California, 14618,

United States

Missing: Anza Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Anza Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Anza Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Anza Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Anza Therapeutics Patents

Anza Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/11/2013

7/7/2015

Point-class cutters, Sensors, Compactness (mathematics), Properties of topological spaces, Mechanical hand tools

Grant

Application Date

8/11/2013

Grant Date

7/7/2015

Title

Related Topics

Point-class cutters, Sensors, Compactness (mathematics), Properties of topological spaces, Mechanical hand tools

Status

Grant

Latest Anza Therapeutics News

Aduro exits clinical hold after trial tweaks quell listeria fears

Nov 22, 2016

Nov 22, 2016 2:58am FDA and Aduro have agreed changes to CRS-207 trial protocols FDA has lifted the partial clinical hold it placed on trials of Aduro Biotech’s CRS-207 cancer vaccine last month. The resolution clears Aduro to resume enrollment in an ongoing Phase I/II trial and push ahead with preparations for a study to test CRS-207 in combination with an anti-PD-1 compound. CRS-207 is made by reengineering Lis­te­ria mono­cy­to­genes to neuter the bacteria and make it express the mesothe­lin protein. This process is intended to ensure the bacteria cannot cause Listeria, but does trigger a cancer-fighting immune response. The snag, for Aduro, is two cases of Listeria did occur in the 350 patients treated prior to the initiation of the partial clinical hold. Those cases were linked to in-dwelling medical device ports, spaces where bacterial biofilms can form. Berkeley, CA-based Aduro got out from under the clinical hold by tweaking its trial protocol to cut the risk of similar cases occurring in the future and ensure it reacts quickly in the event they do. To head off the biofilm threat, Aduro is excluding patients with certain hard-to-remove prosthetic devices from CRS-207 trials. Knowledge of the potential for CRS-207 to cause problems for people with prosthetics goes back years. Anza Therapeutics tested CRS-207 in humans before offloading the asset to Aduro in 2009. The exclusion criteria for an Anza trial protocol filed late in 2007 bar patents with “artificial (prosthetic) joint or other artificial implant or devices that cannot be easily removed” from participating in the study. Aduro has gradually tweaked the wording of the line since starting its own clinical trials of CRS-207 in 2011. The first protocol included a near word-for-word copy of Anza’s line about prosthetics, adding only that “there are some exceptions.” A subsequent trial protocol listed “dental and breast implants and biliary stents and mediports” as the exceptions. In 2013, Aduro tweaked the exclusion criteria to allow patients with prosthetic heart valves and other previously-prohibited implants into its studies, provided the device was placed at least one year ago and hadn’t previously caused infections. The new wording of the exclusion criteria is yet to go live on ClinicalTrials.gov, but Aduro’s statement suggests it will place greater restrictions on the ability of people with prosthetic implants to join its studies. Aduro has also agreed with FDA to extend patient surveillance and give antibiotics to recipients of CRS-207 who may take immunosuppressive drugs. These changes prompted FDA to give Aduro the green light to resume enrolling patients in trials of CRS-207. Aduro plans to start a Phase II trial of CRS-207 in combination with an anti-PD-1 drug in mesothelioma patients in the first half of next year. Read more on

Anza Therapeutics Frequently Asked Questions (FAQ)

  • Where is Anza Therapeutics's headquarters?

    Anza Therapeutics's headquarters is located at 150 Allens Creek Road, Concord.

  • What is Anza Therapeutics's latest funding round?

    Anza Therapeutics's latest funding round is Unattributed VC.

  • How much did Anza Therapeutics raise?

    Anza Therapeutics raised a total of $18M.

  • Who are the investors of Anza Therapeutics?

    Investors of Anza Therapeutics include Sofinnova Partners and Kleiner Perkins Caufield & Byers.

  • Who are Anza Therapeutics's competitors?

    Competitors of Anza Therapeutics include Humanetics, Kereos, CoImmune, Bellicum Pharmaceuticals, Actinobac Biomed, Nora Therapeutics, GlobeImmune, NovaDigm Therapeutics, Pervasis Therapeutics, IASO Pharma and 14 more.

Compare Anza Therapeutics to Competitors

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

I
ISA Pharmaceuticals

ISA Pharmaceuticals (Immune System Activation) is dedicated to fighting cancer and infectious diseases by providing ways to activate the patients immune system. Building on the work by internationally renowned tumor-immunology researcher Professor Kees Melief at the Leiden University Medical Center, the Netherlands, ISA Pharmaceuticals focuses on the development of synthetic peptide vaccines that boost the bodys immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. Thanks to a recent by the Melief-group, clinical studies (phase I/II) are showing highly promising results. The is the use of long peptides in therapeutic vaccines. This synthetic long peptide concept (SLP)aims to enable the activation of both cytotoxic T-cells (killer cells) and T-helper cells, which leads to activity of the immune systems against a tumor.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

I
ImmuRx

ImmuRx is focused on cancer and chronic infectious disease by stimulating both the innate and adaptive halves of the immune system. Per the company, ImmuRx has demonstrated significantly greater immune responses and greater therapeutic benefit than most competing adjuvants in a wide variety of disease indications.

A
Astellas Research Institute of America

Astellas Research Institute of America is focused on cardiology, dermatology, immunology, infectious disease and urology.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.